• Publications
  • Influence
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
TLDR
FOLFIRi and FOLFIRI+Bev offered superior activity to their comparators and were comparably safe, and an infusional schedule of FU should be the preferred irinotecan-based regimen in first-line metastatic colorectal cancer. Expand
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
TLDR
The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS, and these combinations are not recommended for the treatment of mCRC in clinical practice. Expand
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results
TLDR
For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS. Expand
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
TLDR
Analysis of data from two large phase III trials demonstrates that efficacy is not compromised in patients requiring a dose reduction for adverse events, indicating that capecitabine provides a better-tolerated alternative to i.v. 5-FU/leucovorin as treatment for patients with metastatic colorectal cancer. Expand
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.
TLDR
The maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer warrants further study as a novel therapeutic agent for cancer patients. Expand
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.
TLDR
Patients with diffuse large-cell lymphoma treated with m- or M-BACOD were evaluated for pretreatment characteristics predictive for response and survival and two characteristics, poor performance status and massive bulky disease, were negatively associated with response rate in a multivariate analysis. Expand
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
TLDR
Capecitabine results in superior response rate, equivalent TTP and overall survival, an improved safety profile and improved convenience compared with i.v. 5-FU/LV as first-line treatment for MCRC, and is a suitable replacement for i.V.5-FU as the backbone of colorectal cancer therapy. Expand
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
TLDR
An MSI assay that uses data from a commercially available next‐generation sequencing (NGS) panel to determine MSI status is developed and offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD‐L1. Expand
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit
PURPOSE This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cellExpand
...
1
2
3
4
5
...